Helix BioPharma Corp. (TSE:HBP – Get Free Report)’s stock price reached a new 52-week low on Tuesday. The stock traded as low as C$0.75 and last traded at C$0.75, with a volume of 22,051 shares trading hands. The stock had previously closed at C$0.90.
Helix BioPharma Trading Down 9.6%
The stock has a market capitalization of C$64.92 million, a PE ratio of -21.25 and a beta of 1.39. The company has a current ratio of 0.19, a quick ratio of 1.03 and a debt-to-equity ratio of 29.27. The business’s 50-day moving average is C$1.13 and its two-hundred day moving average is C$1.59.
Helix BioPharma (TSE:HBP – Get Free Report) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. On average, analysts predict that Helix BioPharma Corp. will post -0.11 earnings per share for the current year.
About Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The Company’s pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA¿, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA¿, a pre-IND gemcitabine prodrug for advanced solid tumors.
Featured Stories
- Five stocks we like better than Helix BioPharma
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
